This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Oxford/Green Cross NK Cell Program

Oxford BioMedica plc

Description: Oxford BioMedica and Green Cross LabCell are developing gene modified natural killer (NK) cell-based therapeutics.

Deal Structure: Oxford BioMedica and Green Cross
In June 2016, Oxford BioMedica announced that it has entered into a Research & Development Collaboration with Green Cross LabCell (GCLC), a subsidiary of Green Cross Holdings. The collaboration will focus on identifying and developing gene modified natural killer (NK) cell-based therapeutics. This collaboration brings together two clinically validated platform technologies with the aim of generating a pipeline of novel and differentiated cell-based products in areas of serious unmet medical need. Oxford BioMedica is contributing its clinically tested LentiVector gene delivery platform for the efficient modification of immune cells, as well as its expertise in GMP bioprocessing, clinical development and regulatory affairs in ex vivo cell & gene therapy. GCLC is contributing its clinically tested platform for production of highly potent and activated NK cells. During the initial Research Collaboration, Oxford BioMedica and GCLC will...See full deal structure in Biomedtracker

Partners: Green Cross Corporation


Oxford/Green Cross NK Cell Program News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug